{"commentary":{"count":14,"free_build_floor":8,"listing_floor":3,"by_channel":{"youtube":8,"x_thread":4,"podcast":2},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03732703\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"MyDRUG","nct_id":"NCT03732703","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=mydrug-nct03732703. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"MyDRUG","arms":[{"description":"Patients with CDK activating alteration receive Abemaciclib in combination with ixazomib, pomalidomide and dexamethasone (IPd)","label":"Sub-Protocol A1","type":"EXPERIMENTAL"},{"description":"Patients with IDH2 activating mutation receive Enasidenib in combination with ixazomib, pomalidomide and dexamethasone (IPd)","label":"Sub-Protocol B1","type":"EXPERIMENTAL"},{"description":"Patients with the presence of RAF/RAS mutation receive Cobimetinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)","label":"Sub-Protocol C1","type":"EXPERIMENTAL"},{"description":"Patients with presence of FGFR3 activating mutations receive Erdafitinib in combination with ixazomib, pomalidomide and dexamethasone (IPd)","label":"Sub-Protocol D1","type":"EXPERIMENTAL"},{"description":"Patients with t(11;14) translocation will be enrolled in arm E1 and randomized to the venetoclax or the IPd control arm. Patients with relapsed Multiple Myeloma will receive Venetoclax, Ixazomib, Pomalidomide and Dexamethasone every cycle. Each cycle is 28 days long.","label":"Sub-Protocol E1","type":"EXPERIMENTAL"},{"description":"Patients with Non-Actionable Genetic Abnormality receive Daratumumab in combination with ixazomib, pomalidomide and dexamethasone (IPd)","label":"Sub-Protocol Y1","type":"EXPERIMENTAL"},{"description":"Patients with Non-Actionable Genetic Abnormality receive Belantamab mafodotin in combination with ixazomib, pomalidomide and dexamethasone (IPd)","label":"Sub-Protocol Y2","type":"EXPERIMENTAL"},{"description":"Patients with Non-Actionable Genetic Abnormality receive Selinexor in combination with ixazomib, pomalidomide and dexamethasone (IPd)","label":"Sub-Protocol Y3","type":"EXPERIMENTAL"}],"collaborators":["AbbVie","Celgene Corporation","Eli Lilly and Company","Genentech, Inc.","Janssen, LP","Takeda","GlaxoSmithKline","Karyopharm Therapeutics Inc"],"completion_date":{"date":"2024-12-31","type":"ACTUAL"},"conditions":["Relapsed Refractory Multiple Myeloma"],"enrollment":{"count":103,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Abemaciclib, dexamethasone, ixazomib, pomalidomide","type":"DRUG"},{"name":"Enasidenib, dexamethasone, ixazomib, pomalidomide","type":"DRUG"},{"name":"Cobimetinib, dexamethasone, ixazomib, pomalidomide","type":"DRUG"},{"name":"Erdafitinib, dexamethasone, ixazomib, pomalidomide","type":"DRUG"},{"name":"Venetoclax, dexamethasone, ixazomib, pomalidomide","type":"DRUG"},{"name":"Daratumumab, dexamethasone, ixazomib, pomalidomide","type":"DRUG"},{"name":"Belantamab mafodotin, dexamethasone, ixazomib, pomalidomide","type":"DRUG"},{"name":"Selinexor, dexamethasone, ixazomib, pomalidomide","type":"DRUG"}],"last_update":"2025-02-14","lead_sponsor":"Multiple Myeloma Research Consortium","official_title":"Myeloma-Developing Regimens Using Genomics (MyDRUG) (Genomics Guided Multi-arm Trial of Targeted Agents Alone or in Combination With a Backbone Regimen)","overall_status":"COMPLETED","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2024-12-31","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Response Rate - Actionable Genetic Alteration","timeFrame":"Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years"},{"measure":"Overall Response Rate - Non-Actionable Genetic Alteration","timeFrame":"Patients will be evaluated monthly for response from the start of the study until the date of documented disease progression, assessed up to 2 years"}],"references":[{"citation":"Kumar S, Paiva B, Anderson KC, Durie B, Landgren O, Moreau P, Munshi N, Lonial S, Blade J, Mateos MV, Dimopoulos M, Kastritis E, Boccadoro M, Orlowski R, Goldschmidt H, Spencer A, Hou J, Chng WJ, Usmani SZ, Zamagni E, Shimizu K, Jagannath S, Johnsen HE, Terpos E, Reiman A, Kyle RA, Sonneveld P, Richardson PG, McCarthy P, Ludwig H, Chen W, Cavo M, Harousseau JL, Lentzsch S, Hillengass J, Palumbo A, Orfao A, Rajkumar SV, Miguel JS, Avet-Loiseau H. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 Aug;17(8):e328-e346. doi: 10.1016/S1470-2045(16)30206-6.","pmid":"27511158","type":"BACKGROUND"}],"start_date":{"date":"2019-04-01","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Myeloma-Developing Regimens Using Genomics (MyDRUG)","url":"https://clinicaltrials.gov/study/NCT03732703"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/mydrug-nct03732703"}